PriceTargets.com logo

Amicus Therapeutics - FOLD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 84.84%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$10.82 As of 04/22/2024 01:00 AM ET
▲ +0.21 (1.98%)

This chart shows the closing price for FOLD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amicus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FOLD

Analyst Price Target is $20.00
▲ +84.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Amicus Therapeutics in the last 3 months. The average price target is $20.00, with a high forecast of $22.00 and a low forecast of $19.00. The average price target represents a 84.84% upside from the last price of $10.82.

This chart shows the closing price for FOLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Amicus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/18/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$21.00 ➝ $19.00Low
2/29/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$22.00Low
12/19/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$15.00 ➝ $20.00Low
11/9/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$14.00 ➝ $15.00Low
10/10/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $14.00Low
9/29/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$17.00 ➝ $19.00Low
9/29/2023Bank of AmericaBoost Target$16.00 ➝ $19.00Low
3/27/2023Bank of AmericaBoost TargetBuy$16.00 ➝ $17.00Low
3/2/2023UBS GroupBoost TargetBuy$15.00 ➝ $17.00Low
3/2/2023The Goldman Sachs GroupBoost TargetNeutral$10.00 ➝ $11.00Low
1/18/2023BTIG ResearchBoost TargetBuy$14.00 ➝ $16.00Low
11/8/2022Morgan StanleyBoost TargetEqual Weight$14.00 ➝ $15.00Low
9/9/2022Morgan StanleyInitiated CoverageEqual Weight$14.00Low
4/13/2022The Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralHigh
2/24/2022SVB LeerinkLower TargetOutperform$16.00 ➝ $14.00High
1/13/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00 ➝ $16.00Low
1/13/2022Cantor FitzgeraldLower TargetOverweight$16.00 ➝ $15.00Medium
11/15/2021Stifel NicolausUpgradeHold ➝ Buy$12.00 ➝ $16.00High
9/30/2021SVB LeerinkLower TargetMarket Perform$13.00 ➝ $12.00High
9/30/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$17.11 ➝ $16.00High
7/19/2021BTIG ResearchInitiated CoverageBuy$15.00Medium
7/1/2021Chardan CapitalReiterated RatingNeutralMedium
7/1/2021Berenberg BankInitiated CoverageHold$14.00Medium
6/10/2021SVB LeerinkReiterated RatingHoldHigh
5/27/2021Needham & Company LLCInitiated CoverageHoldLow
5/20/2021UBS GroupInitiated CoverageBuy$16.00High
4/19/2021Cantor FitzgeraldUpgradeNeutral ➝ OverweightN/A
4/13/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$17.00 ➝ $17.00High
3/22/2021SVB LeerinkLower TargetMarket Perform$15.00 ➝ $13.00N/A
3/8/2021Stifel NicolausInitiated CoverageHold$13.00N/A
3/3/2021Robert W. BairdReiterated RatingBuyHigh
3/1/2021Stifel NicolausInitiated CoverageHold$13.00 ➝ $13.00High
2/12/2021CitigroupLower Target$27.00 ➝ $16.00Low
2/12/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$30.00 ➝ $15.00Low
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00Low
2/12/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$30.00 ➝ $17.00Low
12/28/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00 ➝ $30.00N/A
12/14/2020SVB LeerinkBoost TargetPositive ➝ Outperform$24.00 ➝ $30.00High
12/10/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $27.00Low
11/11/2020Berenberg BankInitiated CoverageBuy ➝ Hold$21.00High
11/6/2020Robert W. BairdBoost TargetOutperform$20.00 ➝ $25.00Medium
11/6/2020SVB LeerinkBoost TargetOutperform$19.00 ➝ $24.00Medium
10/19/2020CowenReiterated RatingBuy$31.00Medium
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
8/11/2020HC WainwrightReiterated RatingBuy$20.00High
8/11/2020CitigroupBoost TargetBuy$15.00 ➝ $20.00High
6/16/2020HC WainwrightReiterated RatingBuy$20.00Low
6/16/2020BTIG ResearchInitiated CoverageBuy$19.00Low
6/8/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
5/19/2020SVB LeerinkReiterated RatingOutperform ➝ Market Perform$19.00High
5/18/2020JPMorgan Chase & Co.Boost TargetOverweight$18.00 ➝ $21.00High
5/9/2020Chardan CapitalReiterated RatingHold$12.50High
3/5/2020Chardan CapitalReiterated RatingHold$12.50Medium
3/3/2020HC WainwrightReiterated RatingBuy$20.00Low
2/4/2020Cantor FitzgeraldReiterated RatingOverweight$19.00 ➝ $20.00High
1/9/2020Robert W. BairdReiterated RatingBuy$20.00High
1/9/2020HC WainwrightReiterated RatingBuy$20.00High
11/21/2019HC WainwrightReiterated RatingBuy$20.00Medium
11/12/2019HC WainwrightBoost TargetBuy$18.00 ➝ $20.00Low
10/17/2019Cantor FitzgeraldReiterated RatingOverweightMedium
10/14/2019HC WainwrightReiterated RatingBuy$18.00Low
10/10/2019CowenSet TargetBuy$31.00Low
8/1/2019CowenReiterated RatingBuy$31.00Low
8/1/2019HC WainwrightReiterated RatingBuy$18.00High
7/15/2019HC WainwrightSet TargetBuy$18.00High
7/2/2019HC WainwrightReiterated RatingBuy$18.00Medium
6/17/2019HC WainwrightInitiated CoverageBuy ➝ Buy$18.00High
6/5/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00 ➝ $19.00Low
5/8/2019Cantor FitzgeraldSet TargetBuy$20.00Low
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 8 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/26/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/25/2023
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 13 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 20 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $10.82
Low: $10.66
High: $10.91

50 Day Range

MA: $12.12
Low: $10.33
High: $14.00

52 Week Range

Now: $10.82
Low: $9.70
High: $14.57

Volume

3,744,829 shs

Average Volume

3,017,344 shs

Market Capitalization

$3.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Amicus Therapeutics?

The following equities research analysts have issued reports on Amicus Therapeutics in the last twelve months: Bank of America Co., Cantor Fitzgerald, JPMorgan Chase & Co., Morgan Stanley, and StockNews.com.
View the latest analyst ratings for FOLD.

What is the current price target for Amicus Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Amicus Therapeutics in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 84.8%. Cantor Fitzgerald has the highest price target set, predicting FOLD will reach $22.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $19.00 for Amicus Therapeutics in the next year.
View the latest price targets for FOLD.

What is the current consensus analyst rating for Amicus Therapeutics?

Amicus Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FOLD will outperform the market and that investors should add to their positions of Amicus Therapeutics.
View the latest ratings for FOLD.

What other companies compete with Amicus Therapeutics?

Other companies that are similar to Amicus Therapeutics include Turning Point Therapeutics, Alkermes, Geron, BridgeBio Pharma and Madrigal Pharmaceuticals. Learn More about companies similar to Amicus Therapeutics.

How do I contact Amicus Therapeutics' investor relations team?

Amicus Therapeutics' physical mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company's listed phone number is (215) 921-7600 and its investor relations email address is [email protected]. The official website for Amicus Therapeutics is www.amicusrx.com. Learn More about contacing Amicus Therapeutics investor relations.